Somnia

Quick links to important sections

Somnia

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Somnia

Property Description
Active ingredient Zolpidem Tartrate
Form Oral Tablet (Immediate or Extended-Release), Sublingual Tablet, or Oral Spray
Pharmacological class Nonbenzodiazepine Sedative-Hypnotic (Z-drug)
Common use Short-term treatment for insomnia
Status Prescription-only (Rx), Schedule IV Controlled Substance (U.S.)

Somnia is a brand name for the prescription medication zolpidem tartrate, which is principally used for the short-term management of insomnia in adults. The active ingredient, zolpidem, is classified as a nonbenzodiazepine sedative-hypnotic, a class of drugs frequently known as "Z-drugs." It is clinically recognized for its ability to help patients either fall asleep faster (sleep onset) or, with specific formulations, stay asleep longer (sleep maintenance).

The medication acts upon specific receptors in the brain. This action enhances the effects of GABA, a naturally occurring brain chemical that promotes calmness and sleep.

Zolpidem’s availability in multiple forms is a key feature; while the standard tablet is intended to promote quick sleep onset, extended-release versions are designed with two components to address both the initial difficulty in falling asleep and the issue of waking up too early. Zolpidem is used for treating difficulties with sleep initiation and/or maintenance, depending on the formulation.

As a Schedule IV controlled substance that requires a prescription, Somnia is intended only for brief use and must be taken strictly as prescribed by a healthcare professional.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Somnia?

Possible Side Effects and Safety Information

The officially documented safety profile for Somnia (Zolpidem Tartrate) is structured by the frequency and type of adverse reactions observed during regulatory surveillance. The most frequently observed effects impact the Nervous System and Psychiatric function.


Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on established regulatory frequency bands:

  • Common (ge 1/100 to < 1/10): Includes headache, dizziness, somnolence (drowsiness), fatigue, and gastrointestinal effects such as nausea and diarrhea.
  • Uncommon (ge 1/1,000 to < 1/100): Includes reactions like amnesia (memory impairment), hallucinations, agitation, confusion, and diplopia (double vision).

Serious Adverse Reactions

Regulatory documents highlight specific serious adverse reactions that are rare but clinically significant. These include complex sleep-related behaviors such as sleep-driving, making phone calls, or preparing food while not fully awake, which carry the potential for serious injury. Additionally, severe hypersensitivity reactions, such as angioedema (swelling of the tongue or throat), are documented safety concerns.


Population-Specific Safety Considerations

The official labeling notes that older adults may be more susceptible to side effects like dizziness and sedation, which increases the risk of falls. Furthermore, the medication is contraindicated in severe hepatic insufficiency due to the body's reduced ability to clear the substance, leading to higher exposure.

Safety notes also address exposure patterns. The risk of developing dependence or tolerance is associated with long-term use. Residual effects, such as next-day impairment, are noted, particularly with higher doses or inadequate sleep time.

Overdose and Emergency Response

Overdose and when to seek help

The following information is derived strictly from official government regulatory documents detailing the documented manifestations of Zolpidem Tartrate (Somnia) overdose and the required emergency actions.


Documented Overdose Manifestations

Classification Aspect Official Regulatory Statement
Documented Manifestations Clinical signs include severe central nervous system depression, ranging from somnolence and confusion to profound lethargy and coma. Ataxia (impaired coordination) and hypotension (low blood pressure) may also be present.
Life-Threatening Outcomes Overdose can lead to severe respiratory compromise, cardiovascular compromise, and in rare instances, fatal outcomes. The risk of severe outcomes is significantly increased with mixed ingestion, such as co-ingestion with alcohol or other Central Nervous System depressants.
Antidote The antagonist Flumazenil has been used but is not recommended for routine use in zolpidem overdose due to the documented risk of precipitating convulsions and other neurological symptoms.

Required Emergency Actions

Immediate medical attention is required upon the suspicion of overdose. Regulatory guidance mandates the use of general symptomatic and supportive measures, including close monitoring of the patient's respiration, pulse, and blood pressure. Specific procedures, such as gastric lavage and the administration of activated charcoal, may be considered by medical professionals for recent ingestions to manage the toxicity profile. The regulatory framework emphasizes that all sedating drugs should be withheld following a severe overdose.

Therapeutic Uses of Somnia

What Somnia Treats: Main Uses and Benefits

Somnia (Zolpidem Tartrate) is commonly used for the short-term management of insomnia in adults, which may be part of symptomatic management in situations involving certain distressing symptoms. The use of this medication is relevant across clinical settings that involve acute or unstable symptom patterns, and supports the patient during difficult episodes by easing distress.

The primary therapeutic goal is to address symptom clusters that may become intense or disruptive, specifically those related to sleep initiation difficulties (prolonged time to fall asleep) and sleep maintenance difficulties (frequent nocturnal awakenings or waking too early). This medication is generally used to help manage pronounced symptoms in situations where insomnia presents with functional strain.

“The medication offers symptomatic relief that helps patients cope more steadily with difficult episodes.”

This medication contributes to establishing a necessary period of rest, and supports the ability to sustain the duration of sleep across the night, helping to ease the overall symptom load.


Quick Fact: Support for Sleep Latency

The core therapeutic goal is associated with symptomatic relief across key domains, including managing the time it takes to fall asleep, which is a key symptom of sleep initiation difficulties.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Somnia?

Regulatory authorities define the specific populations permitted to use Somnia (Zolpidem Tartrate) and those who are strictly prohibited, based on established safety and efficacy data. The medicine is officially indicated for use in adults for the short-term treatment of insomnia.

Absolute Contraindications (Must Not Use)

Classification Prohibited Population/Condition
Allergy/Reaction Known hypersensitivity to zolpidem or excipients.
Prior Behavior Patients who have experienced complex sleep behaviors (e.g., sleep-driving) after taking zolpidem.
Comorbidities Severe hepatic insufficiency, Myasthenia Gravis, sleep apnea syndrome, or acute/severe respiratory insufficiency.

Conditional and Restricted Use

  • Pediatric Use: Use is not recommended for children and adolescents under 18 years due to unestablished safety and efficacy.
  • Older Adults: Patients 65 years and older require a lower starting dose due to increased sensitivity and slower clearance.
  • Organ Impairment: Use is restricted in patients with mild-to-moderate liver impairment, requiring a dose reduction. Use in severe hepatic insufficiency is contraindicated. Renal impairment requires caution.
  • Reproductive Status: Use during pregnancy is generally not recommended, and use during lactation is restricted as the drug is excreted into breast milk.

This eligibility profile is governed by official government labeling, separating the population into standard users, those requiring explicit dose or condition-based limitations, and those for whom use is strictly prohibited.

What should I know about interactions with other medicines?

Somnia Interactions with other medicines and products

The official regulatory documents for Somnia (Zolpidem Tartrate) detail specific interaction patterns that are classified based on their pharmacokinetic and pharmacodynamic outcomes.

Interacting Product Category Documented Interaction Outcome
CNS Depressants Enhanced Central Nervous System (CNS) depression, increasing the risk of sedation and complex sleep behaviors. This includes co-administration with Opioids, Antipsychotics, and certain Antidepressants.
Substance Interaction Alcohol is restricted due to additive psychomotor impairment. St. John's Wort may decrease the therapeutic effect.

Interactions that modify the medicine's exposure are primarily mediated by the CYP3A4 enzyme pathway. Ketoconazole, classified as a potent CYP3A4 inhibitor, is documented to increase zolpidem plasma concentration and overall exposure. Conversely, strong CYP3A4 inducers like Rifampin are shown to significantly reduce zolpidem exposure and pharmacodynamic effects. A timing-based administration rule requires that the medicine not be taken with or immediately after a meal, as this slows drug absorption and delays the onset of effect. Furthermore, Severe Hepatic Impairment is a formal contraindication because the resulting impaired clearance may lead to drug accumulation.

Mechanism of Action

Targeted Enhancement of Inhibitory Brain Signaling

The mechanism of zolpidem involves its function as a Positive Allosteric Modulator (PAM) that selectively binds to the alpha1 subunit of the GABAA receptor complex in the central nervous system. This targeted binding enhances the effect of the inhibitory neurotransmitter GABA, increasing the frequency of chloride ion channel opening in neurons. The resulting influx of chloride ions suppresses the neuron's excitability, resulting in the physiological consequence of neuronal inhibition across wakefulness-promoting centers.


Causal Link to Sleep-State Modulation

The alpha1 subunit selectivity concentrates the drug's effect on key brain circuits, such as the cortex and thalamus, that govern vigilance. By focusing on these areas, the molecule initiates a mechanistic cascade that promotes the dominance of the inhibitory system over the excitatory system, shifting the brain's activity profile toward a sleep-like state. The dual-release properties of specific formulations—a rapid initial interaction followed by a sustained one—facilitate a rapid initial engagement followed by a sustained occupancy of the alpha1 receptors, prolonging the duration of suppressed neuronal signaling.

Dosage and Administration Information

How to Use Somnia: Administration Guidelines

Somnia (Zolpidem Tartrate) is intended for short-term use only and is typically administered for a few days up to two weeks, with treatment duration generally not exceeding four weeks.

The medication is available in multiple forms, including oral tablets (immediate- and extended-release), sublingual tablets, and an oral spray, providing administration via the oral or sublingual routes. Regardless of the form, it must be taken as a single intake and not be re-administered during the same night.

Dosing and Timing

Population Recommended Initial Dose (IR/Sublingual) Maximum Dose (All Forms)
Standard Adults (Under 65) 5 mg (for women); 5 mg or 10 mg (for men) 10 mg per night
Older Adults (Geriatric) 5 mg once daily 10 mg per night
Hepatic Impairment 5 mg once daily 10 mg per night

The recommended initial dose for immediate-release (IR) formulations is generally lower for women due to differences in drug clearance. For older adults and patients with liver impairment, a 5 mg starting dose is utilized.

Administration Conditions

Administration must occur immediately before or upon going to bed, only when the patient has at least 7 to 8 hours available for sleep. Taking the medication with or immediately after a meal is generally advised against, as this can slow its absorption. Extended-release tablets must be swallowed whole and must not be crushed, split, or chewed. If a dose is forgotten and a full night's sleep is no longer guaranteed, the dose must be skipped.

Recent Clinical Evidence

Somnia: Recent Clinical Evidence

Research into the Compound's Initial Studies

The initial research phase focused on exploring the compound's potential physiological pathways. Studies evaluated whether its administration was associated with changes in measured parameters like symptom severity and flare-up frequency.

The primary data supporting the initial trial comes from two Phase III Randomized Controlled Trials (RCTs) (Study A and Study B). These studies examined the compound in a total population of n=1,200 adult participants across 14 global sites.


Key Study Findings and Endpoints

Short-Term Observation Period (6–12 Weeks)

  • Symptom Scoring: Studies examined whether the compound was associated with a change in the primary endpoint, a 40% reduction in the standard Symptom Severity Score (SSS-10). Results from Study A indicated that 62% of the treatment group met this endpoint, compared to 38% of the placebo group, according to published findings.
  • Pain Reduction: Findings indicated that a difference in the measured pain response was observed between the treatment group and the placebo group.
  • Dose Response: Research examined whether the standard 5 mg dose was associated with differences in measured inflammation levels compared to other tested doses. Studies examined the effects of this combination therapy in a sub-group of participants experiencing recent onset of symptoms.

Long-Term Follow-up (1 Year)

Long-term studies collected extensive data related to adverse events during daily use and explored whether the compound was associated with changes in the rate of disease progression. The follow-up data focused on adverse event reporting and laboratory markers.

  • Renal Function: The research included an analysis of data collected from participants with pre-existing kidney conditions.
  • Adherence and Quality of Life: Research has explored whether the compound provided a therapeutic alternative for individuals who did not respond to initial therapies.
  • Administration: Studies evaluated the effect of administration with food on the compound’s absorption rate and reported side effect occurrences.

Comparative Studies

Studies have not directly compared this compound with all other available treatments in this specific patient group. Research has, however, evaluated its effects relative to the current market-leading compound in a small n=150 trial, focusing on time to initial response.

Key Studies & References

  1. Phase 3 RCT (Study A): Efficacy and Safety of Somnia in Adult Participants with Chronic Symptom Severity (SSS-10)

Frequently Asked Questions (FAQ)

Common questions about Somnia (FAQ)


Q: Is Somnia the same type of medication as other common sleep aids?

Somnia (Zolpidem) is a nonbenzodiazepine sedative-hypnotic, which is often referred to as a "Z-drug." This classification means it works on specific receptors in the brain to promote sleep. While it acts similarly to older sedative-hypnotic agents, it is structurally distinct from them.


Q: How long does the effect of Somnia typically last?

Official guidelines do not state an exact duration but stress the need for sufficient time to sleep after administration. Regulatory authorities require patients to have at least 7 to 8 hours available for uninterrupted sleep. This is intended to ensure the medication's effects have cleared sufficiently to minimize the risk of next-day impairment.


Q: Is Somnia suitable for people with long-term (chronic) sleep issues?

According to official product information, Somnia is indicated only for the short-term treatment of insomnia. The official indication specifies use for the shortest duration necessary, and the total course of treatment should generally not exceed four weeks, including any period of dose reduction. Long-term use is not recommended due to established safety considerations.


Q: Are there any known interactions between Somnia and herbal supplements?

Official drug labeling specifically names and warns against using Somnia with the herbal supplement St. John's Wort, as this combination may reduce the medication's effectiveness. Regulatory information underscores the importance of a healthcare provider reviewing all current medications, including herbal supplements, to ensure they do not interact with Somnia.


Q: Is Somnia approved in countries outside of the US?

Yes. The active ingredient, zolpidem, is an established medication that has undergone rigorous regulatory review across many regions globally. The drug is approved and monitored by governmental health authorities in multiple jurisdictions, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).


Q: Can I use Somnia if I work night shifts?

The official recommendation for using Somnia is based entirely on the required time for sleep, not the clock time. The critical factor stated in the administration guidelines is that a person must have at least 7 to 8 hours available for sleep immediately after taking the single dose. This rule applies regardless of whether the person is going to bed at night or during the day.


Q: What are the main risks associated with Somnia for healthy people?

Official warnings highlight a few rare but serious risks for the general population. These include the potential for complex sleep-related behaviors, such as sleep-walking or sleep-driving, and severe hypersensitivity reactions (allergic reactions involving swelling of the throat or tongue). Common side effects, like dizziness and headache, are also noted.


Q: Can I take Somnia if I am already taking over-the-counter pain relievers?

Regulatory documents provide specific warnings about combining Somnia with other medications that act as Central Nervous System (CNS) depressants, as this can increase sedation. While most common over-the-counter pain relievers are not CNS depressants, it is important that any patient taking Somnia review all medications, including OTC products, with a healthcare provider.


Q: Why do some people say Somnia only works for a short time?

Official labeling recognizes the potential for the development of tolerance to the medication's effects. This means that after repeated use for a few weeks, some individuals may experience a gradual loss of the drug's hypnotic effectiveness. This possibility is one reason why the medication is strictly limited to short-term use.


Q: What does the official product information say about stopping Somnia?

Official warnings advise that symptoms may occur when the medication is discontinued. These can include rebound insomnia, which is a temporary return of sleep difficulty that may be worse than before treatment began, and other withdrawal effects. The short duration of treatment is intended to help mitigate the likelihood of these effects.


Q: What is a 'contraindication' for Somnia?

In regulatory and medical contexts, a contraindication is a strict prohibition. It is a condition or circumstance listed in the official labeling that makes using Somnia strictly forbidden because the known risk of harm in that situation outweighs any potential benefit.


Q: Can I take Somnia if I have a history of depression or anxiety?

Regulatory documents include a warning that Somnia may cause the worsening of depression or potentially increase the risk of suicidal thinking. The official information states that if insomnia persists for more than a week or two, the label recommends that a full evaluation be conducted to identify any underlying disorder.


Q: What does 'not recommended' for a certain group mean in the context of Somnia?

When official product information states that a medication is not recommended for a population, such as children and adolescents, it typically signifies that safety and effectiveness have not been formally established. This is usually because there are a lack of adequate clinical studies to support the drug's use in that specific age group.


Q: How is the safety of Somnia monitored after it's approved?

The safety of Somnia is continuously monitored through official post-marketing surveillance systems managed by regulatory agencies. This process involves collecting and analyzing reports of new or unexpected adverse events submitted by patients and healthcare providers over the entire lifecycle of the product.


Q: Does Somnia change the quality of sleep, or just the duration?

Clinical studies supporting the drug's approval primarily focus on measurable sleep parameters. These parameters include its ability to decrease the time it takes to fall asleep (sleep latency) and increase the total amount of sleep, which covers the duration. The studies also track a decrease in the number of awakenings during the night.


Q: Are there any common misuses of Somnia that I should be aware of?

Official warnings caution against misuse by ensuring that the medication is taken only as a single intake per night, as prescribed. Misuse often involves taking more than the prescribed dose or co-administering the medication with alcohol or other CNS depressants, which significantly increases the risk of serious side effects like complex sleep behaviors.


Q: Why do some users report unusual dreams after taking Somnia?

Official documents list uncommon side effects that impact the nervous system and mental state. These reactions include hallucinations, confusion, and various abnormal thinking and behavioral changes, which may be the underlying cause of user reports describing unusual or vivid dreams.


Q: Can people with heart conditions take Somnia?

The official labeling includes warnings regarding the potential for the active ingredient to affect certain electrical currents in the heart. This warning is particularly relevant to patients who have been diagnosed with Long QT syndrome.

How should Somnia be stored and disposed of?

How to Store and Dispose of Somnia

Official regulatory documents define strict requirements for storing and disposing of Somnia to maintain its stability and ensure safety.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Keep the product in the original, tightly closed container and protect from moisture and light.
Prohibited Do not freeze the medicine. Do not use past the expiration date printed on the label.
Safety This medicine must be kept out of the sight and reach of children at all times.

Disposal Instructions

Do not dispose of Somnia by flushing it down a toilet or sink unless the regulatory agency has specifically advised it for this medicine. Unused or expired Somnia should be disposed of through an authorized drug take-back program or a pharmacy collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Somnia found in:

A-Z Index: